Phase 3 Readout

PHVS: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and S

Name: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and S
Start: 2027-06-01
End: 2027-06-01

June 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 1, 2027
Company: Pharvaris N.V. (PHVS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and S

June 1, 2027

PHVS overview →

Company: Pharvaris N.V. (PHVS)
Indication: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)